AMCP Signs Letter Urging Funds for COVID Vaccine Administration; FDA Recommends EUA for Pfizer-BioNTech COVID-19 Vaccine; CDC Interim Recommendations for Allocating Initial COVID-19 Vaccine; SCOTUS Ruling on Rutledge v. PCMA; AMCP Summary of Medicare Part B MFN Model; AMCP Summary of Medicare Part D Rebate Rule; AMCP Comments on CMS Draft Guidance for CY 2022 Medicare Advantage Capitation Rates, Part C and Part D Payment Policies; Electoral College Formally Designates Joe Biden President-Elect.
On Dec. 12, AMCP joined the Pharmacy Supply and Payment Chain Coalition's letter to Congressional leaders urging them to support the CDC's request for supplemental funding to cover the cost of administering COVID-19 vaccines.
The leaders of 18 pharmacy organizations today issued the following statement following the Food and Drug Administration’s approval of the first Emergency Use Authorization for the COVID-19 vaccine.
On Nov. 30, AMCP submitted comments on CMS draft guidance for Calendar Year (CY) 2022 Medicare Advantage capitation rate and Part C and Part D payment policies. AMCP responded to CMS’s proposed introduction of a COVID-19 measure for the 2023 Part C and Part D performance measure display page and in the Star Ratings program, pending rulemaking.
On November 20, HHS released a Final Rule that amends the discount safe harbor regulation to eliminate protections for price concessions offered by pharmaceutical manufacturers to plan sponsors and pharmacy benefit managers (PBMs) under contract with plan sponsors starting January 1, 2022.
On November 20, HHS released an Interim Final Rule with Comment Period (IFC) establishing a Most Favored Nation (MFN) Model for Medicare Part B drugs. The MFN Model will calculate the payment rate for included drugs based on a price that reflects the lowest per capita GDP-adjusted price among a group of OECD countries, with an additional flat payment based on the average payment for MFN Model drugs in 2019 adjusted quarterly for inflation.